Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
88.840USD
-0.540-0.60%
Close 09-24 16:00（ET）
595.23MMarket Cap
LossP/E TTM
After-hours 16:41 (ET)88.800USD-0.300-0.34%
After-hours 16:41 (ET)About Monopar Therapeutics Inc Company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Monopar Therapeutics Inc Profile
Ticker SymbolMNPR
Company nameMonopar Therapeutics Inc
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Number of employees16
Security typeOrdinary Share
Fiscal year-endDec 19
Address1000 Skokie Blvd Ste 350
CityWILMETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60091-1146
Phone18473880349
Websitehttps://www.monopartx.com/
Ticker SymbolMNPR
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Company Executives of Monopar Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board, Independent Director
Executive Chairman of the Board, Independent Director
15.05K
-6.64%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board, Independent Director
Executive Chairman of the Board, Independent Director
15.05K
-6.64%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board, Independent Director
Executive Chairman of the Board, Independent Director
15.05K
-6.64%
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board, Independent Director
Executive Chairman of the Board, Independent Director
15.05K
-6.64%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board, Independent Director
Executive Chairman of the Board, Independent Director
15.05K
-6.64%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board, Independent Director
Executive Chairman of the Board, Independent Director
15.05K
-6.64%
FAQs
Who are the top five shareholders of Monopar Therapeutics Inc?
The top five shareholders of Monopar Therapeutics Inc are: Dr. Chandler D. Robinson, M.D.
How many institutions hold shares of Monopar Therapeutics Inc (MNPR)?
As of 2026Q1, 147 institutions hold shares of Monopar Therapeutics Inc, with a combined market value of approximately 5.90M, accounting for 88.03% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1082274.00.